PAREXEL - Roland Andersson Discusses Trends at DIA 2016
Roland Andersson, Ph.D., SVP Clinical Research Services at PAREXEL, discusses trends at DIA 2016. DIA this year, I’m seeing a number of different trends. First of all, I think we have away more of a global presence than we usually do- we are seeing a lot of countries being here. We’re also seeing for instance, the Japanese Regulatory Agency, PMDA. We’re also seeing a number of technology companies who are focusing on a particular area- smaller technology companies, for instance, risk-based monitoring and other areas. In terms of trends for drug development, I’m seeing a lot of imaging technology being present. I’m also seeing a lot of technology tools with the ambition of being able to create an end-to-end drug development process. One of the key trends we are seeing at this year’s DIA is that of accelerated approval pathways. PAREXEL with its broad global regulatory footprint is ideally suited to help our clients achieve this.